Interaction between vascular factors and the APOE ε4 allele in predicting rate of progression in alzheimer's disease

Journal of Alzheimer's Disease

Volumn 26, Issue 1, 2011, Pages 127-134

  Mielke, Michelle M ^a   Leoutsakos, Jeannie Marie ^a   Tschanz, Joann T ^b   Green, Robert C ^c   Tripodis, Yorghos ^d   Corcoran, Chris D ^b   Norton, Maria C ^b   Lyketsos, Constantine G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UTAH STATE UNIVERSITY   (United States)

^c Departments of Neurology Medicine (Genetics) Epidemiology   (United States)

^d BOSTON UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; APOE; disease progression; myocardial infarction population based; stroke; vascular factors

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E4;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ANAMNESIS; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL DEMENTIA RATING SUM OF BOX; COGNITION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEMENTIA; DIABETES MELLITUS; DISEASE COURSE; DRUG USE; FEMALE; FOLLOW UP; GENE FREQUENCY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HETEROZYGOTE; HOLM BONFERRONI METHOD; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PREDICTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RATING SCALE; STROKE; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

EID: 80052827558     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110086     Document Type: Article

References (42)

1. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipopro-tein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90, 1977-1981. (Pubitemid 23069980)
2. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923. (Pubitemid 23275809)
3. Bertram L, Tanzi RE (2008) Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 9, 768-778.
4. Anand SS, Xie C, Pare G, Montpetit A, Rangarajan S, McQueen MJ, Cordell HJ, Keavney B, Yusuf S, Hudson TJ, Engert JC (2009) Genetic variants associated with myocardial infarction risk factorsinover8000 individuals fromfive ethnic groups: The INTERHEART Genetics Study. Circ Cardiovasc Genet 2, 16-25.
5. Elosua R, Ordovas JM, Cupples LA, Fox CS, Polak JF, Wolf PA, D'Agostino RA Sr, O'Donnell CJ (2004) Association of APOE genotype with carotid atherosclerosis in men and women: the Framingham Heart Study. J Lipid Res 45, 1868-1875. (Pubitemid 40990879)
6. Niu W, Qi Y, Qian Y, Gao P, Zhu D (2009) The relationship between apolipoprotein E epsilon2/epsilon3/epsilon4 polymorphisms and hypertension: a meta-analysis of six studies comprising 1812 cases and 1762 controls. Hypertens Res 32, 1060-1066.
7. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H (2002) Apolipopro-tein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137, 149-155. (Pubitemid 34827510)
8. Beeri MS, Rapp M, Silverman JM, Schmeidler J, Grossman HT, Fallon JT, Purohit DP, Perl DP, Siddiqui A, Lesser G, Rosendorff C, Haroutunian V (2006) Coronary artery disease is associated with Alzheimer disease neuropathology in APOε4 carriers. Neurology 66, 1399-1404. (Pubitemid 43739650)
9. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y (2009) Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66, 343-348.
10. Martins CA, Oulhaj A, de Jager CA, Williams JH (2005) APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 65, 1888-1893. (Pubitemid 43970105)
11. Craft S, Teri L, Edland SD, Kukull WA, Schellenberg G, McCormick WC, Bowen JD, Larson EB (1998) Acceler-ated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology 51, 149-153. (Pubitemid 28345375)
12. Frisoni GB, Govoni S, Geroldi C, Bianchetti A, Calabresi L, Franceschini G, Trabucchi M (1995) Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol 37, 596-604.
13. Stern Y, Brandt J, Albert M, Jacobs DM, Liu X, Bell K, Marder K, Sano M, Albert S, Del-Castillo Castenada C, Bylsma F, Tycko B, Mayeux R (1997) The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 41, 615-620. (Pubitemid 27212655)
14. Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS (2005) Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol 62, 454-459. (Pubitemid 40349483)
15. Dal Forno G, Rasmusson DX, Brandt J, Carson KA, Brook-meyer R, Troncoso J, Kawas CH (1996) Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol 53, 345-350. (Pubitemid 26110090)
16. Kleiman T, Zdanys K, Black B, Rightmer T, Grey M, Garman K, Macavoy M, Gelernter J, van Dyck C (2006) Apolipopro-tein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Dement Geriatr Cogn Disord 22, 73-82.
17. Bracco L, Piccini C, Baccini M, Bessi V, Biancucci F, Nacmias B, Bagnoli S, Sorbi S (2007) Pattern and progression of cognitive decline in Alzheimer's disease: role of premorbid intelligence and ApoE genotype. Dement Geriatr Cogn Disord 24, 483-491. (Pubitemid 350175910)
18. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT (1996) Apolipoprotein Egenotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 47, 444-448. (Pubitemid 26324041)
19. Treiber KA, Carlson MC, Corcoran C, Norton MC, Breitner JC, Piercy KW, Deberard MS, Stein D, Foley B, Welsh-Bohmer KA, Frye A, Lyketsos CG, Tschanz J (2011) Cognitive stimulation and cognitive and functional decline in Alzheimer's disease: The Cache County Dementia Progression Study. Am J Geriatric Psychiatry, doi: 10.1093/geronb/gbr023.
20. Regan C, Katona C, Walker Z, Hooper J, Donovan J, Livingston G (2006) Relationship of vascular risk to the progression of Alzheimer disease. Neurology 67, 1357-1362. (Pubitemid 44632057)
21. Mielke MM, Rosenberg PB, Tschanz J, Cook L, Corcoran C, Hayden KM, Norton M, Rabins PV, Green RC, Welsh-Bohmer KA, Breitner JC, Munger R, Lyketsos CG (2007) Vascular factors predict rate of progression in Alzheimer disease. Neurology 69, 1850-1858. (Pubitemid 350071146)
22. Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, Steffens DC, Norton MC, Tschanz JT, Plassman BL, Meyer MR, Skoog I, Khachaturian A (1999) APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology 53, 321-331. (Pubitemid 29344354)
23. APA (1987) Diagnostic and statistical manual of mental disorders, American Psychatric Association.
24. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140, 566-572. (Pubitemid 12124384)
25. Lyketsos CG, Galik E, Steele C, Steinberg M, Rosenblatt A, Warren A, Sheppard JM, Baker A, Brandt J (1999) The General Medical Health Rating: abedside global rating of medical comorbidity in patients with dementia. J Am Geriatr Soc 47, 487-491. (Pubitemid 29181378)
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
27. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al. (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260. (Pubitemid 23060253)
28. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
29. Mohs RC, Schmeidler J, Aryan M (2000) Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. Stat Med 19, 1401-1409. (Pubitemid 30346233)
30. Morris JC (1997) Clinical dementia rating:areliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 9 Suppl 1, 173-176; discussion 177-178. (Pubitemid 28045357)
31. Pavlik VN, Doody RS, Massman PJ, Chan W (2006) Influence of premorbid IQ and education on progression of Alzheimer's disease. Dement Geriatr Cogn Disord 22, 367-377. (Pubitemid 44651453)
32. Truelsen T, Lindenstrom E, Boysen G (1994) Comparison of probability of stroke between the Copenhagen City Heart Study and the Framingham Study. Stroke 25, 802-807. (Pubitemid 24111327)
33. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB (1991) Probability of stroke: a risk profile from the Framingham Study. Stroke 22, 312-318.
34. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC (2002) Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59, 880-886.
35. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6, 65-70.
36. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90, 9649-9653. (Pubitemid 23315843)
37. Riley KP, Snowdon DA, Markesbery WR (2002) Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol 51, 567-577.
38. Yip AG, McKee AC, Green RC, Wells J, Young H, Cupples LA, Farrer LA (2005) APOE, vascular pathology, and the AD brain. Neurology 65, 259-265. (Pubitemid 41022371)
39. Sparks DL, Hunsaker JC, 3 rd, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR (1990) Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 11, 601-607.
40. Gromadzka G, Baranska-Gieruszczak M, Sarzynska-Dlugosz I, Ciesielska A, Czlonkowska A (2007) The APOE polymorphism and 1-year outcome in ischemic stroke: genotype-gender interaction. Acta Neurol Scand 116, 392-398. (Pubitemid 350045495)
41. Sarzynska-Dlugosz I, Gromadzka G, Baranska-Gieruszczak M, Ciesielska A, Czlonkowska A (2007) APOE does not predict poor outcome 1 year after ischemic stroke. Neurol Res 29, 64-69. (Pubitemid 46185072)
42. Martinez-Gonzalez NA, Sudlow CL (2006) Effects of apolipoproteinE genotype on outcome after ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 77, 1329-1335. (Pubitemid 44851989)